Anti-proliferative Effects of Vitamin D and Melatonin in Breast Cancer (MELO-D)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01965522 |
|
Recruitment Status :
Completed
First Posted : October 18, 2013
Last Update Posted : June 16, 2017
|
Sponsor:
Juravinski Cancer Center
Information provided by (Responsible Party):
Punam Rana, Juravinski Cancer Center
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Investigators plan to carry out a study to investigate two different pills, Vitamin D and melatonin, and whether they can reduce the spread of cancer cells in the tumors of women with breast cancer. These pills are inexpensive and have very few side effects. A large number of studies using cell cultures and animals have shown that both vitamin D and melatonin can help destroy breast cancer cells. However thoughtful and well-designed studies are necessary on humans to see if they can decrease the spread of breast cancer, and possibly even prevent breast cancer. The proposed study aims to understand the anti-cancer activity of vitamin D and melatonin. This knowledge will assist in creating efficient cancer prevention strategies for Canadians. This study will include women with breast cancer who are being planned for surgery, and will assess whether treatment with vitamin D (dose of 2000 IU per day) in a group of 36 women, or melatonin (dose of 20mg per day) in another group of 36 women, or both pills together in yet another group of 36 women, reduces the spread of cancer cells when compared to a fourth group of 36 women who are treated with sugar pills. To do this we will measure a substance in the blood called Ki67, which provides information about the spread of cancer. Investigators will compare the Ki67 levels in the 4 groups, and all women will receive identical appearing pills so they will not know which treatment they received.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Early Stage Breast Cancer | Drug: Melatonin Drug: Vitamin D Drug: Placebo (melatonin) Drug: Placebo (vitamin D) | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 100 participants |
| Allocation: | Randomized |
| Intervention Model: | Factorial Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | Anti-proliferative Effects of Vitamin D and Melatonin in Breast Cancer |
| Study Start Date : | October 2013 |
| Actual Primary Completion Date : | August 2016 |
| Actual Study Completion Date : | May 2017 |
Resource links provided by the National Library of Medicine
Genetics Home Reference related topics:
Breast cancer
| Arm | Intervention/treatment |
|---|---|
| Experimental: Melatonin and Vitamin D |
Drug: Melatonin
Melatonin 20mg taken orally once daily. This is in the form of one capsule which contains two pills of melatonin, 10 mg each. Drug: Vitamin D Vitamin D 2000 IU taken orally once daily. This is in the form of one capsule which contains two pills of vitamin D, 1000 IU each. |
| Experimental: Placebo and Vitamin D |
Drug: Vitamin D
Vitamin D 2000 IU taken orally once daily. This is in the form of one capsule which contains two pills of vitamin D, 1000 IU each. Drug: Placebo (melatonin) Overencapsulated placebo capsule which contains an inert substance. The capsule appears identical to the capsule which contains melatonin tablets. |
| Experimental: Melatonin and Placebo |
Drug: Melatonin
Melatonin 20mg taken orally once daily. This is in the form of one capsule which contains two pills of melatonin, 10 mg each. Drug: Placebo (vitamin D) Overencapsulated placebo capsule which contains an inert substance. The capsule appears identical to the capsule which contains vitamin D tablets. |
| Placebo Comparator: Placebo and Placebo |
Drug: Placebo (melatonin)
Overencapsulated placebo capsule which contains an inert substance. The capsule appears identical to the capsule which contains melatonin tablets. Drug: Placebo (vitamin D) Overencapsulated placebo capsule which contains an inert substance. The capsule appears identical to the capsule which contains vitamin D tablets. |
Primary Outcome Measures :
- Ki67 [ Time Frame: From time of initial biopsy to the final surgery, which is on average 4 weeks ]The primary outcome is the difference in proliferation rate of Ki67 in the tumour (expressed as the percentage of tumour cells expressing Ki67). Ki67 will be measured on the original core biopsy (pre-treatment) and on the lumpectomy/mastectomy specimen (post-treatment).
Secondary Outcome Measures :
- microRNA [ Time Frame: At the time of surgery compared to time of biopsy, which is on average 4 weeks ]Change in serum profile of microRNA at the time of surgery (lumpectomy or mastectomy, post-treatment) will be compared to the time of initial biopsy (pre-treatment).
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Woman with histologically confirmed invasive breast cancer (ductal, lobular, or mixed)
- Planned to undergo definitive surgery, either lumpectomy or mastectomy in 3 or more weeks
Exclusion Criteria:
- Less than 18 years of age
- Stage IIIB or IV disease
- Inoperable locally advanced or metastatic breast cancer
- Neoadjuvant chemotherapy is intended
- Currently taking vitamin D supplements
- Currently taking melatonin supplements
- Previously taking vitamin D or melatonin supplements within the last 3 months
- Currently taking a multivitamin and not willing to discontinue for the duration of the study
- Hyperparathyroid disease or other calcium disturbance in the past five years
- Active renal stones in the last six months
- Renal failure (creatinine > 190 mmol/L)
- Hypercalcemia (serum calcium > 2.6 mmol/L)
- Known pregnancy
- Participation in another clinical trial where the patient receives any other investigational product
- Unwilling or unable to provide informed consent
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01965522
Locations
| Canada, Ontario | |
| St Joseph's Healthcare Hamilton | |
| Hamilton, Ontario, Canada, L8N 1Y3 | |
| Juravinski Cancer Center | |
| Hamilton, Ontario, Canada, L8V 1C3 | |
Sponsors and Collaborators
Juravinski Cancer Center
| Responsible Party: | Punam Rana, Principal Investigator, Juravinski Cancer Center |
| ClinicalTrials.gov Identifier: | NCT01965522 History of Changes |
| Obsolete Identifiers: | NCT02288806 |
| Other Study ID Numbers: |
MELO-D |
| First Posted: | October 18, 2013 Key Record Dates |
| Last Update Posted: | June 16, 2017 |
| Last Verified: | June 2017 |
Keywords provided by Punam Rana, Juravinski Cancer Center:
|
Breast cancer melatonin vitamin d ki67 |
Additional relevant MeSH terms:
|
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Vitamins Vitamin D Ergocalciferols Melatonin |
Micronutrients Growth Substances Physiological Effects of Drugs Bone Density Conservation Agents Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Central Nervous System Depressants |